Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LA JOLLA PHARMACEUTICAL COLJPC · Entity 124310 | Director · President, CEO & Secretary | April 15, 2019 | April 17, 2019 |
| Odonate Therapeutics, Inc.ODT · Entity 132524 | Director | September 19, 2019 | September 23, 2019 |
| REVELATION BIOSCIENCES, INC.REVB · Entity 8359 | Director | February 11, 2025 | February 13, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LA JOLLA PHARMACEUTICAL CO
Report date April 15, 2019 · Filed April 17, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,263,895 |
Reported balance
After 2019-04-15 transaction · row 1
1 source rowRow 1 · 2019-04-15 · Grant · Acquired 2 · Balance 1,263,895 F1: These shares were acquired on 04/15/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.16 · Expires 2029-04-15 | Direct | 2 |
Reported balance
After 2019-04-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-04-15 · Grant · Acquired 2 · Balance 2 F2: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. |
| Common StockSEC Table I · non-derivative | IndirectBy children | 22,000 |
Reported balance
Holding disclosure · report date 2019-04-15 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 22,000 |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were acquired on 04/15/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
F2: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years.
Odonate Therapeutics, Inc.
Report date September 19, 2019 · Filed September 23, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 151,291 |
Ending reported balance
After 2019-09-19 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-09-19 · Exercise / conversion · Acquired 77,331 · Balance 77,331 F1: The Reporting Person received 77,331 shares of common stock on exercise of incentive units, pursuant to the terms of the Odonate Management Holdings, LLC Equity Incentive Plan. Row 2 · 2019-09-19 · Exercise / conversion · Acquired 73,960 · Balance 151,291 F2: The Reporting Person received 73,960 shares of common stock on exercise of incentive units, pursuant to the terms of the Odonate Management Holdings, LLC Equity Incentive Plan. |
| Incentive UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.54 | Direct | 43,225 |
Reported balance
After 2019-09-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-09-19 · Exercise / conversion · Disposed 78,821 · Balance 43,225 F3: The incentive units vested with respect to 25% of the underlying shares on 12/30/2017, with the remaining shares vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date. F4: The incentive units do not expire. |
| Incentive UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.54 | Direct | 49,391 |
Reported balance
After 2019-09-19 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-09-19 · Exercise / conversion · Disposed 75,385 · Balance 49,391 F5: The incentive units vested with respect to 25% of the underlying shares on 3/2/2018, with the remaining shares vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date. F4: The incentive units do not expire. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person received 77,331 shares of common stock on exercise of incentive units, pursuant to the terms of the Odonate Management Holdings, LLC Equity Incentive Plan.
F2: The Reporting Person received 73,960 shares of common stock on exercise of incentive units, pursuant to the terms of the Odonate Management Holdings, LLC Equity Incentive Plan.
F3: The incentive units vested with respect to 25% of the underlying shares on 12/30/2017, with the remaining shares vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date.
F4: The incentive units do not expire.
F5: The incentive units vested with respect to 25% of the underlying shares on 3/2/2018, with the remaining shares vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date.
REVELATION BIOSCIENCES, INC.
Report date February 11, 2025 · Filed February 13, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 268 |
Reported balance
After 2025-02-11 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2025-02-11 · Grant · Acquired 181 · Balance 268 F2: Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests 100% on date of grant. F1: Shares are held by George Tidmarsh, Trustee George Francis Tidmarsh 2021 Irrevocable Trust |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 87 |
Reported balance
Holding disclosure · report date 2025-02-11 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 87 F1: Shares are held by George Tidmarsh, Trustee George Francis Tidmarsh 2021 Irrevocable Trust |
Filing footnotes · ownership attribution and instrument terms
F1: Shares are held by George Tidmarsh, Trustee George Francis Tidmarsh 2021 Irrevocable Trust
F2: Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests 100% on date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 11, 2025 Filed Feb 13, 2025 23:03 UTC | REVELATION BIOSCIENCES, INC. REVB · Entity 8359 | GrantCommon Stock | 181 | $3.87 | $700.47 |
DisclosureSEC source: 0000950170-25-020097 · ownership.xml · nonDerivative · entry 2 TIDMARSH GEORGE F · CIK 0001287235 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 268 F2 · security: Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests 100% on date of grant. F1 · ownership.nature: Shares are held by George Tidmarsh, Trustee George Francis Tidmarsh 2021 Irrevocable Trust Read SEC document |
| December 08, 2023 Filed Dec 12, 2023 21:48 UTC | REVELATION BIOSCIENCES, INC. REVB · Entity 8359 | SaleCommon Stock | 27,771 | $0.52 | $14,438.14 |
DisclosureSEC source: 0001209191-23-058296 · doc4.xml · nonDerivative · entry 1 TIDMARSH GEORGE F · CIK 0001287235 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Read SEC document |
| October 16, 2023 Filed Oct 17, 2023 20:12 UTC | REVELATION BIOSCIENCES, INC. REVB · Entity 8359 | SaleCommon Stock | 10,957 | $0.66 | $7,242.58 |
DisclosureSEC source: 0001209191-23-052953 · doc4.xml · nonDerivative · entry 1 TIDMARSH GEORGE F · CIK 0001287235 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 42,096 F1 · ownership.nature: Shares are held by George Tidmarsh, Trustee George Francis Tidmarsh 2021 Irrevocable Trust with respect to which George Tidmarsh is a trustee. Read SEC document |
| October 16, 2023 Filed Oct 18, 2023 21:15 UTC | REVELATION BIOSCIENCES, INC. REVB · Entity 8359 | SaleCommon Stock | 1,845 | $0.65 | $1,199.43 |
DisclosureSEC source: 0001209191-23-053102 · doc4.xml · nonDerivative · entry 1 TIDMARSH GEORGE F · CIK 0001287235 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,771 Read SEC document |
| September 28, 2023 Filed Oct 2, 2023 20:09 UTC | REVELATION BIOSCIENCES, INC. REVB · Entity 8359 | SaleCommon Stock | 1,429 | $0.69 | $986.01 |
DisclosureSEC source: 0001209191-23-051037 · doc4.xml · nonDerivative · entry 1 TIDMARSH GEORGE F · CIK 0001287235 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 42,096 F1 · ownership.nature: Shares are held by George Tidmarsh, Trustee George Francis Tidmarsh 2021 Irrevocable Trust with respect to which George Tidmarsh is a trustee. Read SEC document |
| September 18, 2023 Filed Sep 18, 2023 21:18 UTC | REVELATION BIOSCIENCES, INC. REVB · Entity 8359 | SaleCommon Stock | 4,000 | $0.74 | $2,960.00 |
DisclosureSEC source: 0001209191-23-049786 · doc4.xml · nonDerivative · entry 3 TIDMARSH GEORGE F · CIK 0001287235 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,348 Read SEC document |
| September 15, 2023 Filed Sep 18, 2023 21:18 UTC | REVELATION BIOSCIENCES, INC. REVB · Entity 8359 | SaleCommon Stock | 9,500 | $0.73 | $6,935.00 |
DisclosureSEC source: 0001209191-23-049786 · doc4.xml · nonDerivative · entry 2 TIDMARSH GEORGE F · CIK 0001287235 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,348 Read SEC document |
| September 14, 2023 Filed Sep 18, 2023 21:18 UTC | REVELATION BIOSCIENCES, INC. REVB · Entity 8359 | SaleCommon Stock | 12,000 | $0.75 | $9,000.00 |
DisclosureSEC source: 0001209191-23-049786 · doc4.xml · nonDerivative · entry 1 TIDMARSH GEORGE F · CIK 0001287235 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,848 Read SEC document |
| April 18, 2023 Filed Apr 19, 2023 22:00 UTC | REVELATION BIOSCIENCES, INC. REVB · Entity 8359 | PurchaseCommon Stock | 25,000 | $1.16 | $29,000.00 |
DisclosureSEC source: 0001209191-23-024898 · doc4.xml · nonDerivative · entry 2 TIDMARSH GEORGE F · CIK 0001287235 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,848 Read SEC document |
| April 17, 2023 Filed Apr 19, 2023 22:00 UTC | REVELATION BIOSCIENCES, INC. REVB · Entity 8359 | PurchaseCommon Stock | 26,500 | $1.16 | $30,740.00 |
DisclosureSEC source: 0001209191-23-024898 · doc4.xml · nonDerivative · entry 1 TIDMARSH GEORGE F · CIK 0001287235 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,848 F1 · price: Represents the weighted-average price at which shares were purchased within a range between $1.14 and $1.17. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| April 14, 2023 Filed Apr 18, 2023 20:08 UTC | REVELATION BIOSCIENCES, INC. REVB · Entity 8359 | GrantStock Option (Right to Buy) · Derivative | 6,356 | $0.00 Strike: $1.19 | $0.00 |
DisclosureSEC source: 0001209191-23-024646 · doc4.xml · derivative · entry 1 TIDMARSH GEORGE F · CIK 0001287235 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,356 Underlying: Common Stock · 6,356 shares Expires 2033-04-14 F1 · derivative.exercise_date: The stock options vest and become exercisable on the grant date. Read SEC document |
| February 25, 2022 Filed Feb 28, 2022 23:29 UTC | REVELATION BIOSCIENCES, INC. REVB · Entity 8359 | PurchaseCommon Stock | 20,000 | $1.60 | $32,000.00 |
DisclosureSEC source: 0001209191-22-013741 · doc4.xml · nonDerivative · entry 1 TIDMARSH GEORGE F · CIK 0001287235 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 467,156 Read SEC document |
| February 09, 2022 Filed Feb 10, 2022 23:22 UTC | REVELATION BIOSCIENCES, INC. REVB · Entity 8359 | PurchaseCommon Stock | 30,000 | $2.55 | $76,599.00 |
DisclosureSEC source: 0001209191-22-008580 · doc4.xml · nonDerivative · entry 2 TIDMARSH GEORGE F · CIK 0001287235 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 447,156 F1 · price: Represents the weighted-average price at which shares were purchased within a range between $2.53 and $2.57. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| February 08, 2022 Filed Feb 10, 2022 23:22 UTC | REVELATION BIOSCIENCES, INC. REVB · Entity 8359 | PurchaseCommon Stock | 1,000 | $2.54 | $2,540.00 |
DisclosureSEC source: 0001209191-22-008580 · doc4.xml · nonDerivative · entry 1 TIDMARSH GEORGE F · CIK 0001287235 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 417,156 Read SEC document |
| February 07, 2022 Filed Feb 8, 2022 23:52 UTC | REVELATION BIOSCIENCES, INC. REVB · Entity 8359 | PurchaseCommon Stock | 42,100 | $2.61 | $109,779.96 |
DisclosureSEC source: 0001209191-22-007837 · doc4.xml · nonDerivative · entry 2 TIDMARSH GEORGE F · CIK 0001287235 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Disclosed balance after: 1,523,335 F2 · price: Represents the weighted-average price at which shares were purchased within a range between $2.50 and $2.6817. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F1 · ownership.nature: Shares are held by George Tidmarsh, Trustee George Francis Tidmarsh 2021 Irrevocable Trust with respect to which George Tidmarsh is a trustee. Read SEC document |
| February 07, 2022 Filed Feb 9, 2022 21:24 UTC Amendment | REVELATION BIOSCIENCES, INC. REVB · Entity 8359 | PurchaseCommon Stock | 42,100 | $2.61 | $109,779.96 |
DisclosureSEC source: 0001209191-22-008025 · doc4a.xml · nonDerivative · entry 2 TIDMARSH GEORGE F · CIK 0001287235 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 1,523,335 F2 · price: Represents the weighted-average price at which shares were purchased within a range between $2.50 and $2.6817. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F1 · ownership.nature: Shares are held by George Tidmarsh, Trustee George Francis Tidmarsh 2021 Irrevocable Trust with respect to which George Tidmarsh is a trustee. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 23:52 UTC | REVELATION BIOSCIENCES, INC. REVB · Entity 8359 | PurchaseCommon Stock | 7,900 | $2.31 | $18,256.11 |
DisclosureSEC source: 0001209191-22-007837 · doc4.xml · nonDerivative · entry 1 TIDMARSH GEORGE F · CIK 0001287235 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Disclosed balance after: 1,481,235 F1 · ownership.nature: Shares are held by George Tidmarsh, Trustee George Francis Tidmarsh 2021 Irrevocable Trust with respect to which George Tidmarsh is a trustee. Read SEC document |
| February 04, 2022 Filed Feb 9, 2022 21:24 UTC Amendment | REVELATION BIOSCIENCES, INC. REVB · Entity 8359 | PurchaseCommon Stock | 2,000 | $2.45 | $4,900.00 |
DisclosureSEC source: 0001209191-22-008025 · doc4a.xml · nonDerivative · entry 3 TIDMARSH GEORGE F · CIK 0001287235 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 416,156 F3 · shares: The original Form 4, filed on February 8, 2022, is being amended by this Form 4 amendment to include shares purchased directly that were inadvertently omitted in the original filing. Read SEC document |
| February 04, 2022 Filed Feb 9, 2022 21:24 UTC Amendment | REVELATION BIOSCIENCES, INC. REVB · Entity 8359 | PurchaseCommon Stock | 7,900 | $2.31 | $18,256.11 |
DisclosureSEC source: 0001209191-22-008025 · doc4a.xml · nonDerivative · entry 1 TIDMARSH GEORGE F · CIK 0001287235 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 1,481,235 F1 · ownership.nature: Shares are held by George Tidmarsh, Trustee George Francis Tidmarsh 2021 Irrevocable Trust with respect to which George Tidmarsh is a trustee. Read SEC document |
| September 19, 2019 Filed Sep 23, 2019 21:03 UTC | Odonate Therapeutics, Inc. ODT · Entity 132524 | Exercise / conversionIncentive Units · Derivative | 75,385 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001209191-19-050515 · doc4.xml · derivative · entry 4 TIDMARSH GEORGE F · CIK 0001287235 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,391 Underlying: Common Stock · 75,385 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The incentive units vested with respect to 25% of the underlying shares on 3/2/2018, with the remaining shares vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date. F4 · derivative.expiration_date: The incentive units do not expire. Read SEC document |
| September 19, 2019 Filed Sep 23, 2019 21:03 UTC | Odonate Therapeutics, Inc. ODT · Entity 132524 | Exercise / conversionIncentive Units · Derivative | 78,821 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001209191-19-050515 · doc4.xml · derivative · entry 3 TIDMARSH GEORGE F · CIK 0001287235 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,225 Underlying: Common Stock · 78,821 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The incentive units vested with respect to 25% of the underlying shares on 12/30/2017, with the remaining shares vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date. F4 · derivative.expiration_date: The incentive units do not expire. Read SEC document |
| September 19, 2019 Filed Sep 23, 2019 21:03 UTC | Odonate Therapeutics, Inc. ODT · Entity 132524 | Exercise / conversionCommon Stock | 73,960 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-050515 · doc4.xml · nonDerivative · entry 2 TIDMARSH GEORGE F · CIK 0001287235 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,291 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The Reporting Person received 73,960 shares of common stock on exercise of incentive units, pursuant to the terms of the Odonate Management Holdings, LLC Equity Incentive Plan. Read SEC document |
| September 19, 2019 Filed Sep 23, 2019 21:03 UTC | Odonate Therapeutics, Inc. ODT · Entity 132524 | Exercise / conversionCommon Stock | 77,331 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-050515 · doc4.xml · nonDerivative · entry 1 TIDMARSH GEORGE F · CIK 0001287235 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,331 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The Reporting Person received 77,331 shares of common stock on exercise of incentive units, pursuant to the terms of the Odonate Management Holdings, LLC Equity Incentive Plan. Read SEC document |
| April 15, 2019 Filed Apr 17, 2019 17:04 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 2 | $0.00 Strike: $7.16 | $0.00 |
DisclosureSEC source: 0000920465-19-000062 · wf-form4_155553497242392.xml · derivative · entry 3 TIDMARSH GEORGE F · CIK 0001287235 · Director · President, CEO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2 Underlying: Common Stock · 2 shares Expires 2029-04-15 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| April 15, 2019 Filed Apr 17, 2019 17:04 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 2 | $6.09 | $12.18 |
DisclosureSEC source: 0000920465-19-000062 · wf-form4_155553497242392.xml · nonDerivative · entry 1 TIDMARSH GEORGE F · CIK 0001287235 · Director · President, CEO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,263,895 F1 · kind: These shares were acquired on 04/15/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| March 29, 2019 Filed Apr 2, 2019 19:07 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 94 | $0.00 Strike: $6.43 | $0.00 |
DisclosureSEC source: 0000920465-19-000057 · wf-form4_155424641950028.xml · derivative · entry 3 TIDMARSH GEORGE F · CIK 0001287235 · Director · President, CEO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94 Underlying: Common Stock · 94 shares Expires 2029-03-29 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| March 29, 2019 Filed Apr 2, 2019 19:07 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 94 | $5.47 | $514.18 |
DisclosureSEC source: 0000920465-19-000057 · wf-form4_155424641950028.xml · nonDerivative · entry 1 TIDMARSH GEORGE F · CIK 0001287235 · Director · President, CEO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,263,893 F1 · kind: These shares were acquired on 03/29/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| March 15, 2019 Filed Mar 19, 2019 17:08 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 195 | $0.00 Strike: $7.64 | $0.00 |
DisclosureSEC source: 0000920465-19-000055 · wf-form4_155302968832111.xml · derivative · entry 2 TIDMARSH GEORGE F · CIK 0001287235 · Director · President, CEO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195 Underlying: Common Stock · 195 shares Expires 2029-03-15 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| March 15, 2019 Filed Mar 19, 2019 17:08 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 195 | $6.49 | $1,265.55 |
DisclosureSEC source: 0000920465-19-000055 · wf-form4_155302968832111.xml · nonDerivative · entry 1 TIDMARSH GEORGE F · CIK 0001287235 · Director · President, CEO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,263,799 F1 · kind: These shares were acquired on 3/15/19 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 17:33 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 261 | $0.00 Strike: $5.70 | $0.00 |
DisclosureSEC source: 0000920465-19-000049 · wf-form4_155173878033378.xml · derivative · entry 3 TIDMARSH GEORGE F · CIK 0001287235 · Director · President, CEO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261 Underlying: Common Stock · 261 shares Expires 2029-02-28 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 17:33 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 261 | $4.85 | $1,265.85 |
DisclosureSEC source: 0000920465-19-000049 · wf-form4_155173878033378.xml · nonDerivative · entry 1 TIDMARSH GEORGE F · CIK 0001287235 · Director · President, CEO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,263,604 F1 · kind: These shares were acquired on 02/28/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 18:10 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 239 | $0.00 Strike: $6.23 | $0.00 |
DisclosureSEC source: 0000920465-19-000034 · wf-form4_155061783002173.xml · derivative · entry 3 TIDMARSH GEORGE F · CIK 0001287235 · Director · President, CEO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239 Underlying: Common Stock · 239 shares Expires 2029-02-15 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 18:10 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 239 | $5.30 | $1,266.70 |
DisclosureSEC source: 0000920465-19-000034 · wf-form4_155061783002173.xml · nonDerivative · entry 1 TIDMARSH GEORGE F · CIK 0001287235 · Director · President, CEO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,263,343 F1 · kind: These shares were acquired on 02/15/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| January 31, 2019 Filed Feb 4, 2019 18:13 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 246 | $0.00 Strike: $6.04 | $0.00 |
DisclosureSEC source: 0000920465-19-000029 · wf-form4_154932202371074.xml · derivative · entry 3 TIDMARSH GEORGE F · CIK 0001287235 · Director · President, CEO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246 Underlying: Common Stock · 246 shares Expires 2029-01-31 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| January 31, 2019 Filed Feb 4, 2019 18:13 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 246 | $5.13 | $1,261.98 |
DisclosureSEC source: 0000920465-19-000029 · wf-form4_154932202371074.xml · nonDerivative · entry 1 TIDMARSH GEORGE F · CIK 0001287235 · Director · President, CEO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,284,446 F1 · kind: These shares were acquired on 01/31/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 21:56 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 174,000 | $0.00 Strike: $5.99 | $0.00 |
DisclosureSEC source: 0000920465-19-000018 · wf-form4_154847138928307.xml · derivative · entry 1 TIDMARSH GEORGE F · CIK 0001287235 · Director · President, CEO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,000 Underlying: Common Stock · 174,000 shares Expires 2029-01-23 F1 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| January 15, 2019 Filed Jan 17, 2019 20:52 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 874 | $0.00 Strike: $6.75 | $0.00 |
DisclosureSEC source: 0000920465-19-000012 · wf-form4_154777632884773.xml · derivative · entry 3 TIDMARSH GEORGE F · CIK 0001287235 · Director · President, CEO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 874 Underlying: Common Stock · 874 shares Expires 2029-01-15 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| January 15, 2019 Filed Jan 17, 2019 20:52 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 874 | $5.74 | $5,016.76 |
DisclosureSEC source: 0000920465-19-000012 · wf-form4_154777632884773.xml · nonDerivative · entry 1 TIDMARSH GEORGE F · CIK 0001287235 · Director · President, CEO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,284,200 F1 · kind: These shares were acquired on 01/15/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| January 07, 2019 Filed Jan 9, 2019 21:29 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | PurchaseCommon Stock | 436 | $5.85 | $2,550.60 |
DisclosureSEC source: 0000920465-19-000011 · wf-form4_154708736639403.xml · nonDerivative · entry 6 TIDMARSH GEORGE F · CIK 0001287235 · Director · President, CEO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,283,326 Read SEC document |
| January 07, 2019 Filed Jan 9, 2019 21:29 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | PurchaseCommon Stock | 700 | $5.85 | $4,095.00 |
DisclosureSEC source: 0000920465-19-000011 · wf-form4_154708736639403.xml · nonDerivative · entry 5 TIDMARSH GEORGE F · CIK 0001287235 · Director · President, CEO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,282,890 Read SEC document |
| January 07, 2019 Filed Jan 9, 2019 21:29 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | PurchaseCommon Stock | 397 | $5.85 | $2,322.45 |
DisclosureSEC source: 0000920465-19-000011 · wf-form4_154708736639403.xml · nonDerivative · entry 4 TIDMARSH GEORGE F · CIK 0001287235 · Director · President, CEO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,282,190 Read SEC document |
| January 07, 2019 Filed Jan 9, 2019 21:29 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | PurchaseCommon Stock | 98 | $5.85 | $573.30 |
DisclosureSEC source: 0000920465-19-000011 · wf-form4_154708736639403.xml · nonDerivative · entry 3 TIDMARSH GEORGE F · CIK 0001287235 · Director · President, CEO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,281,793 Read SEC document |
| January 07, 2019 Filed Jan 9, 2019 21:29 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | PurchaseCommon Stock | 287 | $5.85 | $1,678.95 |
DisclosureSEC source: 0000920465-19-000011 · wf-form4_154708736639403.xml · nonDerivative · entry 2 TIDMARSH GEORGE F · CIK 0001287235 · Director · President, CEO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,281,695 Read SEC document |
| January 07, 2019 Filed Jan 9, 2019 21:29 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | PurchaseCommon Stock | 82 | $5.85 | $479.70 |
DisclosureSEC source: 0000920465-19-000011 · wf-form4_154708736639403.xml · nonDerivative · entry 1 TIDMARSH GEORGE F · CIK 0001287235 · Director · President, CEO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,281,408 Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 19:51 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 154 | $0.00 Strike: $9.43 | $0.00 |
DisclosureSEC source: 0000920465-19-000002 · wf-form4_154656309146409.xml · derivative · entry 3 TIDMARSH GEORGE F · CIK 0001287235 · Director · President, CEO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154 Underlying: Common Stock · 154 shares Expires 2028-12-31 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 19:51 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 154 | $8.02 | $1,234.39 |
DisclosureSEC source: 0000920465-19-000002 · wf-form4_154656309146409.xml · nonDerivative · entry 1 TIDMARSH GEORGE F · CIK 0001287235 · Director · President, CEO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,281,326 F1 · kind: These shares were acquired on 12/31/2018 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 20:04 UTC | Odonate Therapeutics, Inc. ODT · Entity 132524 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $14.08 | $0.00 |
DisclosureSEC source: 0001209191-19-001507 · doc4.xml · derivative · entry 1 TIDMARSH GEORGE F · CIK 0001287235 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2028-12-31 F1 · derivative.exercise_date: The stock options vest and become exercisable on December 31, 2019, subject to the Reporting Person's continued service to the Issuer through such date. Read SEC document |
| December 14, 2018 Filed Dec 17, 2018 20:28 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 112 | $0.00 Strike: $12.80 | $0.00 |
DisclosureSEC source: 0000920465-18-000067 · wf-form4_154509652289022.xml · derivative · entry 3 TIDMARSH GEORGE F · CIK 0001287235 · Director · President, CEO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112 Underlying: Common Stock · 112 shares Expires 2028-12-14 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| December 14, 2018 Filed Dec 17, 2018 20:28 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 112 | $10.88 | $1,218.56 |
DisclosureSEC source: 0000920465-18-000067 · wf-form4_154509652289022.xml · nonDerivative · entry 1 TIDMARSH GEORGE F · CIK 0001287235 · Director · President, CEO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,281,172 F1 · kind: These shares were acquired on 12/14/2018 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| November 30, 2018 Filed Dec 3, 2018 21:56 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 100 | $0.00 Strike: $14.47 | $0.00 |
DisclosureSEC source: 0000920465-18-000062 · wf-form4_154389217444229.xml · derivative · entry 3 TIDMARSH GEORGE F · CIK 0001287235 · Director · President, CEO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 Underlying: Common Stock · 100 shares Expires 2028-11-30 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.